On February 5, 2018 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported plans to report fourth quarter and full year 2017 financial results on February 21, 2018 (Press release, Ligand, FEB 5, 2018, View Source [SID1234523736]). Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth Quarter and Full Year 2017 Earnings Call

What: Ligand conference call to discuss financial results and provide general business updates

When: Wednesday, February 21, 2018

Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Conference Call: (833) 591-4752 within the U.S.
(720) 405-1612 outside the U.S.
Conference ID – 2391528

Webcast:

Live conference call webcast and replay accessible at www.ligand.com

On February 5, 2018 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) reported that the Company will participate in the following upcoming investment conferences (Press release, Inovio, FEB 5, 2018, View Source [SID1234523735]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BIO CEO & Investor Conference
Presentation
Dr. J. Joseph Kim, President & CEO
February 13, 2018, 2:15 PM ET
New York, NY

RBC Capital Markets Global Healthcare Conference
Presentation
Dr. J. Joseph Kim, President & CEO
February 22, 2018, 10:30 AM ET
New York, NY

Live and archived versions of the presentations will be available through the Inovio Investor Relations Events page at View Source

On February 5, 2018 BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, reported that it will present preliminary Phase I data on its investigational anti-PD-1 antibody, tislelizumab, in urothelial carcinoma (bladder cancer) at the upcoming 2018 Genitourinary Cancers Symposium, to be held February 8-10 in San Francisco (Press release, BeiGene, FEB 5, 2018, View Source;p=RssLanding&cat=news&id=2330396 [SID1234523733]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Title: Preliminary Results from Patients with Urothelial Carcinoma (UC) in a Phase 1A/1B study of BGB-A317, an Anti-PD-1 Monoclonal Antibody
Abstract: 445; Poster Board: G16
Presenter: Shahneen Sandhu, M.D.
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Date & Times: Friday, February 9, 2018 at 12:15-1:45 PM (PT) and 6:00-7:00 PM (PT)
Location: Moscone West Building, San Francisco

About Tislelizumab (BGB-A317)
Tislelizumab is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. Tislelizumab has demonstrated high affinity and specificity for PD-1. It is differentiated from the currently approved PD-1 antibodies in an engineered Fc region, which is believed to minimize potentially negative interactions with other immune cells. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. BeiGene and Celgene Corporation have a global strategic collaboration for tislelizumab for solid tumors outside of Asia (except Japan).

On February 5, 2018 Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") reported that it will be attending and presenting at the BIO CEO & Investor Conference being held on February 12 – 13, 2018 at the New York Marriott Marquis (Press release, Actinium Pharmaceuticals, FEB 5, 2018, View Source [SID1234523729]). Details of Actinium’s presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, February 13, 2018
Time: 9:15 AM ET
Room: Odets, 4th Floor
Venue: New York Marriott Marquis, 1535 Broadway, New York, NY 10036

Management will be conducting 1-on-1 meetings during the conference. To arrange a meeting with Actinium please contact, Steve O’Loughlin, Actinium’s Principal Financial Officer at [email protected] or utilize the conference’s partnering system View Source

On February 5, 2018 RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA) therapeutic platform reported that it will give a webcast presentation at the BIO CEO and Investor Conference(Press release, RXi Pharmaceuticals, FEB 5, 2018, View Source [SID1234523727]). RXi’s President and CEO, Dr. Geert Cauwenbergh, will highlight the Company’s therapeutic platform and its business strategy to advance the development of a new class of cancer therapeutics, using adoptive cell transfer (ACT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Developing Self-Delivering RNAi (sd-rxRNA) for Immuno-oncology
Track and location: Oncology, Room: Odets
Date and Time: Monday, February 12, 2018, 2:15 pm ET
Presenter: Dr. Geert Cauwenbergh, President and CEO

Now in its 20th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The conference will take place February 12-13, 2018 at the New York Marriott Marquis in New York City.

The link for the webcast may be found on the Company’s website under the "Investors – Events and Presentations" section at www.rxipharma.com.